<DOC>
	<DOCNO>NCT01066442</DOCNO>
	<brief_summary>To compare efficacy BF2.649 placebo ( 12 week Double-Blind Phase ) ass long term safety efficacy maintenance ( 9 month Open-Label Extension Phase ) BF2.649 improvement excessive daytime sleepiness patient diagnose Parkinson 's Disease .</brief_summary>
	<brief_title>Efficacy Safety BF2.649 Excessive Daytime Sleepiness ( EDS ) Parkinson 's Disease</brief_title>
	<detailed_description>As measure change baseline Epworth Scale Scores ( ESS ) Week 12 Week 51 , patient diagnose EDS Parkinson 's Disease .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Patients document history Parkinson 's disease accord UPDRS , fluctuator nonfluctuator patient , Hoehn Yahr score &lt; 5 ; stabilize optimal antiparkinsonian treatment unmodified 4 week prior study entry ; present Excessive Daytime Sleepiness indicate ESS &gt; or=12 Patients know diagnosis degenerative parkinsonian syndrome ( e.g . Progressive supranuclear palsy , multisystemic atrophy , corticobasal degenerescence , diffuse Lewy 's Body dementia ) Patients shift work , chronic occasional sleep deprivation , circadian rhythm disorder Patients severe depression indicate ( BDI &gt; = 16 ) suicidal risk ( BDI item G &gt; 0 ) depression treat less 8 week Patients cognitive impairment</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Excessive Daytime Sleepiness ( EDS )</keyword>
	<keyword>Parkinson 's Disease</keyword>
</DOC>